Real-life Treatment Outcomes of Ravulizumab in PNH (PNH-RECORD)

September 22, 2026 updated by: AstraZeneca

Real-life Treatment Outcomes of Ravulizumab in Polish Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH). Prospective and Retrospective, Multicenter, Non-interventional Study.

The PNH-RECORD study, a Polish multicenter observational (non-interventional), open-label, retrospective with prospective follow-up.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Detailed Description

PNH-RECORD study aims to aims to collect data on the patients' characteristics and clinical outcomes of ravulizumab administered in the scope of routine clinical practice in PNH.

Study Type

Observational

Enrollment (Actual)

64

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Bialystok, Poland
        • Research Site
      • Brzozów, Poland
        • Research Site
      • Bydgoszcz, Poland
        • Research Site
      • Gdansk, Poland
        • Research Site
      • Krakow, Poland
        • Research Site
      • Lodz, Poland
        • Research Site
      • Lublin, Poland
        • Research Site
      • Opole, Poland
        • Research Site
      • Szczecin, Poland
        • Research Site
      • Warsaw, Poland
        • Research Site
      • Wałbrzych, Poland
        • Research Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Adult (aged ≥18) patients with PNH

Description

Inclusion Criteria:

  1. Adult (aged ≥18) patients with PNH receiving ravulizumab treatment in the frames of NDP in Poland.
  2. Patients willing to participate in the study and signed ICF.

Exclusion Criteria:

  1. Those who participated in ravulizumab clinical trial in the past, and/or those who participated/plans to participate in clinical trial on/after the date of first ravulizumab infusion through NDP.
  2. Cognitive incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: COHORT
  • Time Perspectives: RETROSPECTIVE

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Ravulizumab group

Open-label

open-label arm with ravulizumab administrated within the scope of routine clinical practice

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Change in LDH levels from index date (first dose of ravulizumab) at every 6 month
Time Frame: up to 36 months
up to 36 months
Proportion of patients achieving or remaining at LDH<1.5 ULN at every 6 month
Time Frame: up to 36 months
up to 36 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of transfusion-free patients from index date at every 6 month
Time Frame: up to 36 months
up to 36 months
Number of blood units used per patient-year
Time Frame: up to 36 months
up to 36 months
To present patients characteristics
Time Frame: Baseline

Mean age (years) at PNH diagnosis

Baseline
To present patients characteristics
Time Frame: Baseline

Mean age (years) at index date

Baseline
To present patients characteristics
Time Frame: Baseline

Proportion (%) of men and women

Baseline
To present patients characteristics
Time Frame: Baseline

Mean body mass index (kg/m²)

Baseline
To present clinical characteristics
Time Frame: Baseline

Mean and median (years) duration of PNH

Baseline
To present clinical characteristics
Time Frame: Baseline

Mean and median (months) time from diagnosis to complement inhibitors treatment initiation

Baseline
To present clinical characteristics
Time Frame: Baseline

Proportion (%) of patients with complication of haemolysis, thrombosis, serious vascular event andaplastic anemia

Baseline
To present clinical characteristics
Time Frame: Baseline

Proportion (%) of patients naïve to complement inhibitors

Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 6, 2025

Primary Completion (Estimated)

August 1, 2028

Study Completion (Estimated)

August 1, 2028

Study Registration Dates

First Submitted

August 9, 2024

First Submitted That Met QC Criteria

October 8, 2024

First Posted (Actual)

October 9, 2024

Study Record Updates

Last Update Posted (Actual)

September 23, 2026

Last Update Submitted That Met QC Criteria

September 22, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • D9289R00001

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

IPD Sharing Time Frame

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

IPD Sharing Access Criteria

When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.